The Future of GDNF in Parkinson's Disease
Main Authors: | Fredric P. Manfredsson, Nicole K. Polinski, Thyagarajan Subramanian, Nicholas Boulis, Dustin R. Wakeman, Ronald J. Mandel |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-12-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2020.593572/full |
Similar Items
-
Astrocyte-derived GDNF is a potent inhibitor of microglial activation
by: Sandra Moreira Rocha, et al.
Published: (2012-09-01) -
Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits
by: Soledad Marton, et al.
Published: (2019-03-01) -
Non-toxic HSC Transplantation-Based Macrophage/Microglia-Mediated GDNF Delivery for Parkinson’s Disease
by: Cang Chen, et al.
Published: (2020-06-01) -
Pre-α-pro-GDNF and Pre-β-pro-GDNF Isoforms Are Neuroprotective in the 6-hydroxydopamine Rat Model of Parkinson's Disease
by: Anna-Maija Penttinen, et al.
Published: (2018-06-01) -
Effects of glial cell line-derived neurotrophic factor (GDNF) on mouse fetal ventral mesencephalic tissue
by: Nevalainen, Nina
Published: (2008)